Vall D'hebron Institute Of Oncology
Clinical trials sponsored by Vall D'hebron Institute Of Oncology, explained in plain language.
-
New immunotherapy combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis phase 2 trial is testing two immunotherapy drugs, durvalumab and tremelimumab, alone or together, in 60 people with colorectal or endometrial cancer. The goal is to see if these drugs can shrink tumors or slow cancer growth. The study focuses on patients with different genet…
Phase: PHASE2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of cell therapy called p95HER2.CAR-TECH2Me for people with advanced HER2-positive breast, gastric, or endometrial cancers that have spread. The treatment uses a patient's own immune cells, which are modified in a lab to better recogniz…
Phase: PHASE1 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC